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RParkinson's disease is a neurodegenerative disease that causes the death of dopaminergic neurons in the
substantia nigra. The resulting dopamine deficiency in the basal ganglia leads to a movement disorder that is
characterized by classical parkinsonian motor symptoms. Parkinson's disease is recognized as the most common
neurodegenerative disorder after Alzheimer's disease.
PD ethiopathogenesis remains to be elucidated and has been connected to genetic, environmental and immuno-
logic conditions.
The past decade has provided evidence for a significant role of the immune system in PD pathogenesis, either
through inflammation or an autoimmune response. Several autoantibodies directed at antigens associated
with PD pathogenesis have been identified in PD patients. This immune activation may be the cause of, rather
than a response to, the observed neuronal loss.
Parkinsonian motor symptoms include bradykinesia, muscular rigidity and resting tremor. The non-motor fea-
tures include olfactory dysfunction, cognitive impairment, psychiatric symptoms and autonomic dysfunction.
Microscopically, the specific degeneration of dopaminergic neurons in the substantia nigra and the presence of
Lewy bodies, which are brain deposits containing a substantial amount of α-synuclein, have been recognized.
The progression of Parkinson's disease is characterized by aworsening ofmotor features; however, as the disease
progresses, there is an emergence of complications related to long-term symptomatic treatment.
The available therapies for Parkinson's disease only treat the symptoms of the disease. Amajor goal of Parkinson's
disease research is the development of disease-modifying drugs that slow or stop the neurodegenerative process.
Drugs that enhance the intracerebral dopamine concentrations or stimulate dopamine receptors remain the
mainstay treatment for motor symptoms.
Immunomodulatory therapeutic strategies aiming to attenuate PDneurodegeneration have become an attractive
option and warrant further investigation.
© 2016 Published by Elsevier B.V.Keywords:
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1. Introduction
Parkinson's disease is a neurodegenerative disease that results in the
death of dopaminergic neurons in the substantia nigra pars compacta
(SNpc). The resulting dopamine deficiency within the basal ganglia
leads to a movement disorder characterized by classical parkinsonian
motor symptoms.
Parkinson's disease was first medically described as a neurological
syndrome by James Parkinson in 1817, although some aspects of
Parkinson's disease were reported in earlier descriptions [1]. For exam-
ple, Sylvius de la Boë wrote of resting tremor and Sauvages described
festination [2,3]. Much earlier, traditional Indian texts from approxi-
mately 1000 BC and ancient Chinese sources also provided descriptions
that were reminiscent of Parkinson's disease [4,5]. Over 50 years later,
Jean-Martin Charcot was more thorough in his descriptions and distin-
guished bradykinesia as a separate cardinal feature of the illness [6].
2. Epidemiology
Parkinson's disease is recognized as themost common neurodegen-
erative disorder after Alzheimer's disease [7,8]. The incidence of
Parkinson's disease ranges from 10 to 18 per 100,000 person-years [9].
Gender is an established risk factor, with a male-to-female ratio of
approximately 3:2 [10]. Ethnicity is also a risk factor for the disease. In
the USA, the incidence is highest in people of Hispanic ethnic origin,
followed by non-Hispanic Whites, Asians and Blacks [9]. Age is the
greatest risk factor for the development of Parkinson's disease. The
prevalence and incidence increase nearly exponentially with age and
peak after 80 years of age [11,12]. This trendhas important public health
implications; as the aging population and life expectancy increase
worldwide, the number of people with Parkinson's disease is expected
to increase by more than 50% by 2030 [7].
3. Ethiopathogenesis
Currently, PD ethiopathogenesis remains to be elucidated, and the
destruction of dopaminergic neurons in PD has been connected to aU
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Fig. 1. Risk factors for the development of Parkinson's disease. Results of epidemiological studies
the risk of developing Parkinson's disease (left). Findings of genome-wide association studies
influence risk for developing Parkinson's disease (right). The strongest genetic risk factor is t
than 5. The interplay between environmental and genetic risk factors is under investigation. O
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variety of factors, including genetic, environmental and immunological
conditions.
Genetic factors have been identified in familiar forms of PD, which
contribute to approximately 10% of PD cases [13,14]. Environmental fac-
tors that were shown to be associatedwith a decreased riskwere tobac-
co smoking, coffee drinking, non-steroidal anti-inflammatory drug use,
calcium channel blocker use, and alcohol consumption [15]. Factors that
increase the risk of developing PD were pesticide exposure, prior head
injury, rural living, β-blocker use, agricultural occupation, and well-
water drinking [15].
Furthermore, the results of epidemiological studies [15] showed that
the use of anti-inflammatory medications, specifically non-steroidal
anti-inflammatory drugs, reduced the risk of developing Parkinson's
disease, supporting the hypothesis that inflammation might promote
an underlying disease process (Fig. 1).
Currently, PD etiopathogenesis remains to be elucidated. Recently,
reviews of the current literature have brought to light evidence for the
possible role of the immune system, specifically autoimmune mecha-
nisms, in the ethiopathogenesis of PD [16]. Previously, it was believed
that PD is not mediated by autoimmune mechanisms [17]. However,
data accumulated over the past decade regarding immune alterations
in PD increased the interest in pursuing such an association. A series
of independent observations has led to the convergence of the view
that innate and adaptive immune mechanisms might play a role in the
development of PD [18].
Neuroinflammation is a characteristic feature of Parkinson's
disease pathology, but it has yet to be established whether neuro-
inflammation promotes or protects from neurodegeneration. A
significant increase in the level of innate immune components, in-
cluding complement and cytokines (e.g., IL-1, IL-2, IL-6, and TNF),
in the substantia nigra and cerebrospinal fluid (CSF) of PD patients
has been observed [18]. Elevation of γ/δ + T cells in the peripheral
blood and CSF of PD patients was also reported [19]. Benkler et al.
[20] then further pursued this quest and found evidence suggest-
ing that an autoimmune mechanism, which may be mediated via
humoral responses, might play a role in the ethiopathogenesis of
PD.have revealed various environmental exposures that increase (OR N1) or decrease (OR b1)
have identified genetic risk factors, which are polymorphisms within certain genes that
he Asn370Ser mutation of β-glucocerebrosidase, which is associated with an OR greater
R = odds ratio. (From: Lancet 2015;386:896:912).
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3D.V. Armando et al. / Autoimmunity Reviews xxx (2016) xxx–xxxOver the last decade, several autoantibodies directed at antigens as-
sociated with or related to PD pathogenesis have been identified in PD
patients, including antibodies directed at melanin [21], a-synuclein
[22,23], and GM1 ganglioside [24].
Interestingly, a recent placebo-controlled study demonstrated that
GM1-ganglioside supplementation was effective in improving tremor-
related motor functions, thus supporting a possible role for these anti-
bodies in the pathogenesis of tremor in PD [24].
Autoreactive antibodies associated with PD have been found in the
plasma and brain; a post-mortem analysis of brains from PD patients
and controls showed that IgG was bound to dopaminergic neurons in
tissues from patients with PD [25].
One potential target structure for an immune attack against dopami-
nergic neurons is the pigment neuromelanin (NM) that accumulates in
dopaminergic neurons as a by-product of catecholamine metabolism
[26].
Oberlander et al. recently showed that NM triggers the functional DC
maturation in vitro, as NM-treatedDCswere able to trigger a proliferative
T cell response. They also showed that DCs can phagocytose NM [27].
These experiments demonstrate that thefirst criterion for DCs to ini-
tiate an adaptive autoimmune response directed against NM-associated
structures was fulfilled. Koutsilieri et al. [28] hypothesize that activated
DCs migrate from the brain into the cervical lymph node, where they
present the potential (auto-)antigens to T and B cells. The recognition
of NM as a pathogen or dangerous molecule and its uptake by DCs
would allow the DCs to migrate, and its presentation in the cervical
lymph nodes triggers an adaptive autoimmune response if NM-
reactive T or B cells are present. This autoimmune response against
NMwould be directed against NM-rich cells in the brain, leading to do-
paminergic cell death. This auto-aggressive loop would be enhanced by
NM-triggered activation of microglia [29,30], resulting in an amplifica-
tion of the adaptive immune response against NM and the local reacti-
vation of the immigrating effector T cells (Fig. 2). There is accumulating
evidence for an immunogenic role of NM in PD pathogenesis. Antibod-
ies directed at catecholamine-basedmelanins have been detected in the
sera from PD patients [21].U
N
C
O
R
R
E
C
Fig. 2.Howactivation of DCs byNMcould trigger autoimmunity directed at dopaminergic neuro
from the brain into the cervical lymph nodes where they present NM to B- and T-lymphocytes
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In another study, CSF derived auto-Abs that reactwith dopaminergic
neurons in the substantia nigra were present in 78% of patients com-
pared with 3% of the controls [31].
Moreover, the CSF of PD patients exerted a cytotoxic effect on dopa-
minergic neurons, which enhanced the substantia nigra degeneration in
a time- and dose-dependent manner [31,32]. This cytotoxic effect was
further demonstrated by neuronal labelling with IgG, which correlated
with neurodegeneration in PD [25].
Early experimental evidence in favour of an autoimmune back-
ground of PD came from Chen et al., who reported that the transfer of
plasma antibodies isolated from PD patients to the substantia nigra of
rats induced a marked loss of dopaminergic neurons. In contrast, ani-
mals that were treated with antibodies from healthy controls exhibited
much less neuronal damage, suggesting that autoantibodies that recog-
nize dopaminergic cells are present in patients with PD [33].
Furthermore, several immune-mediated mechanisms were pro-
posed to explain the possible mechanisms by which autoantibodies
may induce dopaminergic cell death, such as activation of apoptosis,
enhanced complement function, accelerated attack of the surround-
ing microglia cells [31,32,34,35], and competitive binding inhibition
[36,37].
Microglia cells, the tissue macrophage population of the brain, are
the main glial cell type that participates in the inflammatory response
in the brain. Microglial activation through an FCγ receptor pathway
can be induced by IgG derived from PD patients, which subsequently
causes substantia nigra cell injury [34]. The plausible notorious effect
of antibodies on the dopaminergic system was further highlighted in a
series of in vitro and in vivo studies utilizing synthetic antibodies
(Abs) [36]. These engineered Abswere able to bind native dopamine re-
ceptors and competitively inhibit the dopamine receptors' ability to
bind their natural agonists [37,38].
Taken together, these results might suggest a role for autoanti-
bodies, which are a prominent feature of autoimmunity, in the
ethiopathogenesis of PD. However, recent studies suggest that this
immune activation may be the cause of, rather than a response to,
the observed neuronal loss.ns. Contact ofDCswithNM triggers thematuration of these cells that subsequentlymigrate
.
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4. Clinical features
Parkinsonian motor symptoms include bradykinesia, muscular ri-
gidity and resting tremor [39]. The non-motor features include olfactory
dysfunction, cognitive impairment, psychiatric symptoms, sleep disor-
ders and autonomic dysfunction.
Non-motor features are also frequently present in Parkinson's dis-
ease before the onset of the classical motor symptoms (Fig. 1) [40].
The premotor phase can be prolonged; for example, the average latency
between the onset of the early symptoms and occurrence of parkinso-
nian motor symptoms is 12–14 years [40].
In late-stage Parkinson's disease, treatment-resistant motor and
non-motor features are prominent and include axial motor symptoms,
such as postural instability, freezing of gait, falls, dysphagia, and speech
dysfunction. After approximately 17 years of disease, up to 80% of pa-
tients with Parkinson's disease have a freezing of gait and falls, and up
to 50% of patients report choking [41]. Dementia is particularly preva-
lent, occurring in 83% of patients with Parkinson's disease who have
had a disease duration of 20 years [42] (Fig. 3).
5. Histopathology
The loss of dark pigmentation in the substantia nigra and frontal
atrophy are typical examples of macroscopic brain aberrations that de-
velop in PD [43].
Microscopically, two predominant features have been recognized: a
specific degeneration of dopaminergic neurons in the substantia nigra
and the presence of Lewy bodies, which are brain deposits that contain
a substantial amount of α-synuclein [43]. In its misfolded state,
α-synuclein becomes insoluble and aggregates to form intracellular in-
clusions within the cell body (Lewy bodies) and processes (Lewy
neurites) of neurons [44]. Lewy pathology is not restricted to the
brain, but can also be found in the spinal cord and peripheral nervous
system [45].
6. Diagnosis
A clinical diagnosis of Parkinson's disease is based on the presence of
parkinsonian motor features, namely, bradykinesia, rigidity and resting
tremor.
Strategies to develop biomarkers for the diagnosis of Parkinson's dis-
ease are under investigation, particularly to enable diagnosis early in the
disease course, even before the onset ofmotor symptoms. Potential clin-
ical markers include olfactory impairment, as measured by standardU
N
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Fig. 3. Clinical symptoms and time course of Parkinson's disease progression. Diagnosis of Parkin
by a premotor or prodromal phase of 20 years ormore. This prodromal phase is characterized by
and with disease progression, causing clinically significant disability. Axial motor symptoms, su
disease. Long-term complications of dopaminergic therapy, including fluctuations, dyskinesia an
cognitive impairment; RBD = REM sleep behaviour disorder. (From: Lancet 2015;386:896:912
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methods, such as the University of Pennsylvania's smell identification
test [40]. The proposed pathological markers are being tested on the
basis of earlier findings of α-synuclein within the peripheral nervous
system. The concentrations of α-synuclein, DJ-1, tau and β-amyloid
[46,47], aswell as theβ-glucocerebrosidase activity in the cerebrospinal
fluid are being tested as potential biochemical biomarkers of early
Parkinson's disease [48,49] (Fig. 4).
Candidate imaging markers include positron emission tomography
(PET) or single photon emission computed tomography (SPECT)
methods tomeasure the reduction in the number of SNpc dopaminergic
nerve terminals projecting to the striatum [50]. StandardMRI has amar-
ginal role in Parkinson's disease diagnosis, but high and ultra-high-field
(7 Tesla) MRI combined with advanced techniques, such as diffusion
tensor imaging, are being explored for early diagnosis of Parkinson's
disease [51,52].
For people with family members with a known monogenic form of
Parkinson's disease, genetic testing can assist in the diagnosis.
A single measure might not suffice for an accurate and early diagno-
sis of such a complex disease. Instead, a combination of imaging, bio-
chemical and genetic biomarkers might be required.
7. Prognosis
The progression of Parkinson's disease is characterized by the
worsening of motor features, which can initially be managed with
symptomatic therapies. However, as the disease progresses, there is
an emergence of complications related to long-term symptomatic treat-
ment, includingmotor and non-motor fluctuations, dyskinesia and psy-
chosis [41]. Symptoms of late-stage Parkinson's disease substantially
contribute to disability and are strong predictors of a need for admission
to an institution and mortality [53].
8. Treatment
The available therapies for Parkinson's disease only treat the symp-
toms of the disease. A major goal of Parkinson's disease research is the
development of disease-modifying drugs that slow or stop the underly-
ing neurodegenerative process. Drugs that can slow or stop the neuro-
degenerative process in Parkinson's disease are not yet available, but
such disease-modifying drugs are anticipated to be most effective if pa-
tients can be diagnosed and treated during this prodromal premotor pe-
riod. Drugs that enhance intracerebral dopamine concentrations or
stimulate dopamine receptors remain the mainstay treatment for
motor symptoms. These drugs include levodopa, dopamine agonists,son's disease occurswith the onset ofmotor symptoms (time 0 years) but can be preceded
specific non-motor symptoms. Additional non-motor features develop following diagnosis
ch as postural instability with frequent falls and freezing of gait, tend to occur in advanced
d psychosis, also contribute to disability. EDS=excessive daytime sleepiness; MCI=mild
).
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Fig. 4. Potential biomarkers for diagnosis of Parkinson's disease. A variety of biomarkers for Parkinson's disease diagnosis are currently under investigation. These biomarkers can be
classified as clinical, imaging, pathological, biochemical and genetic. Midbrain hyperechogenicity detected by transcranial sonography is a proposed diagnostic biomarker for
Parkinson's disease, but many experts have found this method to have reliability and replicability issues. Combinations of biomarkers are likely to be necessary for accurate diagnosis
of premotor or early PD. 11C-DTBZ = 11C-dihydrotetrabenazine; CSF = cerebrospinal fluid; DTI = diffusion tensor imaging; 123I-CIT = 123I-2β-carbomethoxy-3β-(4-
iodophenyl)tropane; 123I-MIBG = 123I-metaiodobenzylguanidine; MLPA = multiplex ligation-dependent probe amplification; MW=molecular weight; PET = positron emission
tomography; RBD = rapid eye movement sleep behaviour disorder; SPECT = single photon emission computed tomography; UPSIT = University of Pennsylvania's smell
identification test. (From: Lancet 2015;386:896:912).
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monoamine oxidase type B inhibitors and, less commonly, amantadine
[54,55]. Because none of these drugs have proven to be neuroprotective
or disease-modifying, therapy does not need to be started at the time of
diagnosis for all patients. However, there is little justification for delay.
Treatment should be initiated when symptoms cause disability or dis-
comfort to the patient, with the goal of improving function and quality
of life.
The past decade has provided accumulating evidence for a signifi-
cant role of the immune system in PD pathogenesis, either through in-
flammation or an autoimmune response. Thus, immunomodulatory
therapy strategies aiming to attenuate PD disease progression have be-
come an attractive option and warrant further investigation. However,
the negative results of non-steroidal anti-inflammatory drugs in late
PD [56] strongly suggest that early immunomodulation is the key to
preventing PD onset and progression.
Minocycline, a broad-spectrum tetracycline antibiotic, has been tested
in experimental models and PD patients. Minocycline effectively crosses
the blood–brain barrier (BBB) and shows potent anti-inflammatory ef-
fects in neurotoxin models of PD [57]. A randomized, double-blind,
Phase II clinical trial showed that minocycline offers a clinical benefit to
early PD patients, which warrants further consideration of minocycline
for use in Phase III clinical trials [58].
Leucine-rich repeat kinase 2 (LRRK2) is an enzyme that is highly
expressed in peripheral macrophages and monocytic cells, as well as
central microglia, suggesting a functional role for LRRK2 in the innate
immune system [59,60]. Inhibition or attenuation of LRRK2 is a
promising therapeutic strategy as an anti-inflammatory treatment
for PD.
Peroxisome proliferator-activated receptor gamma coactivator 1-
alpha (PGC-1α) is a potential new target for anti-inflammatory therapy
in PD patients. PGC-1α activity is mainly controlled by the peroxisome
proliferator-activated receptors (PPARs), 5′AMP-activated protein kinase
(AMPK), and sirtuin 1 (Sirt1) [61]. Hence, pharmacological activators for
these proteins have the potential to exert anti-inflammatory effects by
activating PGC-1α. These activators include fibrates and rosiglitazone
(PPAR) [62,63], metformin [64], pyrroloquinoline quinone [65],
5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) (AMPK)
[66] and resveratrol (Sirt1) [67].Please cite this article as: Armando DV, et al, Parkinson's disease: Auto
dx.doi.org/10.1016/j.autrev.2016.07.022E
DAs PPAR agonists (fibrates and rosiglitazone) and AMPK activators(metformin and AICAR) are already routinely used in clinical practice
for the treatment of metabolic syndrome and type 2 diabetes, these
drugs could be readily translated from animal models to PD patients.
Preclinical CNS distribution and efficacy studies using inflammatory an-
imal models of PD will be sufficient to warrant clinical trials on these
drugs.
9. Conclusions
Parkinson's disease is a debilitating disease of unknown cause,
despite major scientific and therapeutic advances. The extensive
damage to the dopaminergic system in PD seems to be intercon-
nected with genetics, environmental and immunological factors,
which is described as a mosaic of many autoimmune diseases
[68]. In this review, we pursued the evidence for immune- and
autoimmune-mediated mechanisms that are associated with PD.
A unique observation indicated that olfactory dysfunction may be
a consequence of an autoimmune mechanism. As decreased olfac-
tion is one of the earliest non-motor signs of PD, this observation
might shed more light on a possible association between autoim-
munity and PD.
Theprevalence of several brain-associated autoantibodies in the sera
of PD patients further support the possible role of immunoglobulin-
mediated autoimmune mechanisms in the ethiopathogenesis of PD.
Not only can these autoantibodies serve as biomarkers of disease
but our renewed understanding of the nature of this complex dis-
ease might also be useful for the early diagnosis and treatment of
PD patients. It is even safe to say that novel therapeutics targeted
at specific autoantibodies may be able to differentiate between PD
subgroups. Further studies to evaluate a larger number of patients
and preferably a wider profile of brain-associated autoantibodies
might enable a better understanding of the precise ethiopathological
mechanism of PD.
Thus, although PD pathogenesis remains to be fully elucidated, it
seems that the inflammation and neuronal degeneration associated
with PD could be induced by autoimmune mechanisms, mainly via
brain-specific auto-Abs.immunity and neuroinflammation, Autoimmun Rev (2016), http://
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Take-home messages
• Parkinson's disease is a neurodegenerative disease that causes the
death of dopaminergic neurons in the substantia nigra pars compacta
(SNpc). The resulting dopamine deficiency in the basal ganglia leads
to a movement disorder that is characterized by classic parkinsonian
motor symptoms.
• PD ethiopathogenesis remains to be elucidated and has been connect-
ed to genetic, environmental and immunological conditions. Recently,
the role of autoimmune mechanisms in the ethiopathogenesis of PD
has garnered more attention. Thus, it seems that neuronal degenera-
tion could be induced by autoimmune mechanisms, mainly via
brain-specific autoantibodies.
• Parkinsonian motor symptoms include bradykinesia, muscular rigidity
and resting tremor. The non-motor features include olfactory dysfunc-
tion, cognitive impairment, psychiatric symptoms and autonomic
dysfunction. Olfactory impairment is one of the first symptoms and
allows an early diagnosis of PD many years before the onset of motor
symptoms.
• Microscopically, two predominant features have been recognized: a
specific degeneration of dopaminergic neurons in the substantia nigra
and the presence of Lewy bodies, which are brain deposits containing
a substantial amount of α-synuclein.
• Therapies for Parkinson's disease only treat the symptoms of the dis-
ease. Drugs that enhance the intracerebral dopamine concentrations
(levodopa) or stimulate dopamine receptors (dopamine agonists) re-
main the mainstay treatment for motor symptoms. A major goal of
Parkinson's disease research is the development of disease-modifying
drugs that stop the neurodegenerative process.
If NM-reactive lymphocytes are present, they get activated (primed)
and secrete NM-specific antibodies (B cells) or exert NM-specific
cytotoxic functions (T cells). Activation of microglia by NMwould re-
sult in a proliferation of NM-specific T cells after contact with NM-
presenting microglia. NM-specific antibodies and T cells may recog-
nize NM-positive neurons and trigger their degradation. (From: J
Neural Transm 2013;120:75–81).
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